Cell Therapeutics (CTIC) ADC Cell Therapeutics (11 lettori)
- Creatore Discussione tucciotrader
- Data di Inizio
s66
Forumer attivo
questo post nato da uno che ha venduto tempo fà le azioni , sarebbe meglio lasciarlo perdere ! infatti è solo una jattura ,meglio passare altrove ! http://www.investireoggi.it/forum/q...zo-questi-falsari-di-chiacchiere-vt77906.html
Lucky15
Nuovo forumer
Intanto, ci becchiamo un'altra parte segreta del Form Q-10 che per Cell potrà essere nota solo dopo il 27 marzo 2016. Ed il tempo passa...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 5, 2013
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Cell Therapeutics, Inc.
File No. 1-12465 - CF#29798
_____________________ Cell Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 2, 2013.
Based on representations by Cell Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded
information from the following exhibit will not be released to the public for the time period specified:
Exhibit 10.7 through March 27, 2016
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Elizabeth M. Murphy
Secretary
Ultima modifica:
guly
Forumer storico
solita tattica dilatatoria del bandito.ormai la conosciamo.sono anni che fanno queste cose.rinvii,nuovi studi,altri farmaci messi avanti dopo i soliti fallimenti,studi fatti a *****.SOLO PER CONTINUARE LE LORO MANOVRE SPORCHE.fate attenzione ai basher che invece lodano il ceo e la sua banda.IGNORATE certi soggetti che spalleggiano la societa' in questo gioco ai danni degli azionisti.non date retta ai loro post.che vadano su altri forum a spalleggiare questa banda.tanto ormai sono definitivamente sputtanati-
Ultima modifica:
guly
Forumer storico
e la banda continua il gioco.jb e il fratellino esperto in materia fanno accordi solo per shortare il titolo o fare altri danni agli azionisti.
Ultima modifica:
s66
Forumer attivo
STI 4 FALLITI ANCORA A SECRETARE LE LORO PUTTANATE ? LA SEC E LA CONSOB SONO DA DENUNCIARE X DANNI PERMANENTI ! NON SI PUO' PERMETTERE CERTE SCEMENZE VENGANO SECRETATE ? MI PORTATE UN ELENCO DI CHI AGISCE COME QUESTI TRUFFATORI ? LA SEC è STATA GIA' SPUTTANATA + VOLTE ,IN QUANTO HANNO PRESO LORO DIPENDENTI A GOZZOVIGLIARE SUI SITI PORNO DI MEZZO MONDO INVECE DI CONTROLLARE LE SOCIETA' QUOTATE ! DITELO AL FARNETICATORE CHE SI FIRMA CON UN NOME DA FRACITO !
Ultima modifica:
ghiottolux
Forumer attivo
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)
SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, has notified CTI and issued a statement on their website stating that CTI's patient access scheme has been approved by the Department of Health and the appeal stage of this appraisal topic is suspended. The draft final appraisal document (FAD) and evaluation report have been removed from the NICE website, since it is no longer relevant.
NICE has agreed that the Appraisal Committee will consider the new evidence on the cost effectiveness of PIXUVRI at its meeting on 11 September 2013.
Cell Therapeutics Inc.: News Release
SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, has notified CTI and issued a statement on their website stating that CTI's patient access scheme has been approved by the Department of Health and the appeal stage of this appraisal topic is suspended. The draft final appraisal document (FAD) and evaluation report have been removed from the NICE website, since it is no longer relevant.
NICE has agreed that the Appraisal Committee will consider the new evidence on the cost effectiveness of PIXUVRI at its meeting on 11 September 2013.
Cell Therapeutics Inc.: News Release
ghiottolux
Forumer attivo
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)
SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). Pixantrone has been classified by AIFA for use in hospitals and additional details on the pricing and reimbursement conditions for PIXUVRI in Italy will be provided coincident with the publication of the "Determina" of AIFA in the Official Gazette, which is expected to take 6 to 8 weeks.
Cell Therapeutics Inc.: News Release
SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). Pixantrone has been classified by AIFA for use in hospitals and additional details on the pricing and reimbursement conditions for PIXUVRI in Italy will be provided coincident with the publication of the "Determina" of AIFA in the Official Gazette, which is expected to take 6 to 8 weeks.
Cell Therapeutics Inc.: News Release